Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jul 16;10(4):296-306.
doi: 10.1093/ehjcvp/pvae026.

Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries

Markus Wallner  1 , Mattia Emanuele Biber  2   3 , Davide Stolfo  2   4 , Gianfranco Sinagra  4 , Lina Benson  2 , Ulf Dahlström  5 , Soffia Gudbjörnsdottir  6   7 , Francesco Cosentino  2   8 , Peter G M Mol  9 , Giuseppe M C Rosano  10 , Javed Butler  11   12 , Marco Metra  13 , Lars H Lund  2   8 , Giulia Ferrannini  2 , Gianluigi Savarese  2   8
Affiliations
Observational Study

Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries

Markus Wallner et al. Eur Heart J Cardiovasc Pharmacother. .

Abstract

Aims: To assess the use and associations with outcomes of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in a real-world population with heart failure (HF) and type 2 diabetes mellitus (T2DM).

Methods and results: The Swedish HF Registry was linked with the National Diabetes Registry and other national registries. Independent predictors of GLP-1 RA use were assessed by multivariable logistic regressions and associations with outcomes were assessed by Cox regressions in a 1:1 propensity score-matched cohort. Of 8188 patients enrolled in 2017-21, 9% received a GLP-1 RA. Independent predictors of GLP-1 RA use were age <75 years, worse glycaemic control, impaired renal function, obesity, and reduced ejection fraction (EF). GLP-1 RA use was not significantly associated with a composite of HF hospitalization (HHF) or cardiovascular (CV) death regardless of EF, but was associated with a lower risk of major adverse CV events (CV death, non-fatal stroke/transient ischaemic attack, or myocardial infarction), and CV and all-cause death. In patients with body mass index ≥30 kg/m2, GLP-1 RA use was also associated with a lower risk of HHF/CV death and HHF alone.

Conclusions: In patients with HF and T2DM, GLP-1 RA use was independently associated with more severe T2DM, reduced EF, and obesity and was not associated with a higher risk of HHF/CV death but with longer survival and less major CV adverse events. An association with lower HHF/CV death and HHF was observed in obese patients. Our findings provide new insights into GLP-1 RA use and its safety in HF and T2DM.

Keywords: Glucagon-like peptide-1 receptor agonists; Heart failure; Registry; Safety; SwedeHF; Type 2 diabetes.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
Figure 1
Figure 1
Independent predictors of GLP-1 RA use. Abbreviations as in Table 1.
Figure 2
Figure 2
Outcome analysis. PS, propensity score; HR, hazard ratio; CI, confidence interval; HF, heart failure; CV, cardiovascular; MACE, major adverse cardiovascular events; TIA, transient ischaemic attack; GLP-1 RA, glucagon-like peptide-1 receptor agonists.
Figure 3
Figure 3
Subgroup analysis for the primary composite outcome performed in the propensity score-matched cohort. Abbreviations as in Table 1.
See this image and copyright information in PMC

References

    1. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699–703. - PubMed
    1. Tomasoni D, Vitale C, Guidetti F, Benson L, Braunschweig F, Dahlstrom U, Melin M, Rosano GMC, Lund LH, Metra M, Savarese G. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry. Eur J Heart Fail; 10.1002/ejhf.3112. Published online ahead of print 22 December 2023. - DOI - PubMed
    1. Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776–785. - PubMed
    1. Savarese G, Butler J, Lund LH, Bhatt DL, Anker SD. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovasc Res 2022;118:2231–2252. - PubMed
    1. Packer M. Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure? Eur J Heart Fail 2018;20:627–629. - PubMed

Publication types

MeSH terms